Abstract：Objective To evaluate the curative effect and prognosis of sakubitril valsartan in treating patients with heart failure with preserved ejection fraction (HFpEF) and primary hypertension.Methods Sixty-three patients with primary hypertension with HFpEFwere chosen from Xinjiang Provincial Corps Hospital between January 2018 and June 2020 and divided into the experimental group (n=32) and control group (n=31). The experimental group was given sakubitril valsartan, while the control group was treated with valsartan. Both groups were followed up for 3 months before the level of N-terminal pro-brain natriuretic peptide (NT-proBNP), NYHA classification of heart function and 6-minute walk test (6MWT), blood pressure, left atrial diameter (LAD), E/A ratio, left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF) were observed.Results The distance of 6MWT in the experimental group was improved more significantly than that in the control group [(516.8±47.5)m vs. (425.7±68.5)m], so was the ratio of E/A[(0.97±0.15) vs. (0.87±0.16)].The level of NT-proBNP in the experimental group was lower than that of the control group (2528.3±761.3)pg/ml vs. (4897.8±966.3) pg/ml. The rate of cardiac function improvement in the treatment group was 87.5%, which was significantly higher than that in the control group (61.2%). The level of blood pressure in both groups was significantly decreased, but there was no significant difference between the two groups after treatment. LVEF, LAD and LVEDD were not statistically significant between the two groups after treatment.Conclusions Sakubitril valsartan can effectively relieve clinical symptoms, improve the distance of 6MWT and E/A ratio, and reduce NT-proBNP levels in patients of primary hypertension with HFpEF.
Ponikowski P, Voors A A, Anker S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)[J]. Eur J Heart Fail, 2016, 18(8): 891-975.
Buggey J,Alenezi F,Yoon H J,et al. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization[J]. ESC Heart Fail, 2017,4( 4):432-439.
[7]
Dunlay S M,Roger V L,Redfield M. Epidemiology of heart failure with preserved ejection fraction[J].Nat Rev Cardiol, 2017, 14(10):591-602.
Teng T K, Tay W T, Dahlstrom U, et al.Different relationships between pulse pressure and mortality in heart failure with reduced,midrange and preserved ejection fraction[J].Int J Cardiol,2018,25(4):203-209.
[13]
Sartipy U,Dahlstrm U,Fu M,et al. Atrial fibrillation in heart failure with preserved,midrange,and reduced ejection fraction[J].JACC Heart Fail,2017,5(8):565-574.
[14]
Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: REDHF study [J]. Eur J Heart Fail, 2018, 20(2):268-277.
2020, Vol. 31 
